Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nogapendekin Alfa Inbakicept + Standard of Care vs Standard of Care in First-Line Advanced NSCLC
NCT07524257Phase 3Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
A Phase 3 trial of nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC), sponsored by ImmunityBio, Inc.. Planned start May 2026; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07524257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524257.